|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
21
|
|
pubmed:dateCreated |
2008-11-4
|
|
pubmed:abstractText |
AQ4N is a novel prodrug that is selectively bioreduced to AQ4, a topoisomerase II inhibitor, in hypoxic tumor. This study assessed the maximum tolerated dose and pharmacokinetics of AQ4N when administered weekly in patients with advanced cancers.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Nov
|
|
pubmed:issn |
1078-0432
|
|
pubmed:author |
pubmed-author:BeeramMuraliM,
pubmed-author:DesaiKavitaK,
pubmed-author:GoelSanjayS,
pubmed-author:HaigentzMissakM,
pubmed-author:LalaniAlshad SAS,
pubmed-author:ManiSridharS,
pubmed-author:MiliánMaría LML,
pubmed-author:PapadopoulosKyriakos PKP,
pubmed-author:SarantopoulosJohnJ,
pubmed-author:TolcherAnthonyA,
pubmed-author:WongAlvinA
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
14
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
7110-5
|
|
pubmed:meshHeading |
pubmed-meshheading:18981010-Adult,
pubmed-meshheading:18981010-Aged,
pubmed-meshheading:18981010-Aged, 80 and over,
pubmed-meshheading:18981010-Anthraquinones,
pubmed-meshheading:18981010-Antineoplastic Agents,
pubmed-meshheading:18981010-Drug Administration Schedule,
pubmed-meshheading:18981010-Fatigue,
pubmed-meshheading:18981010-Female,
pubmed-meshheading:18981010-Humans,
pubmed-meshheading:18981010-Male,
pubmed-meshheading:18981010-Maximum Tolerated Dose,
pubmed-meshheading:18981010-Middle Aged,
pubmed-meshheading:18981010-Nausea,
pubmed-meshheading:18981010-Neoplasms,
pubmed-meshheading:18981010-Prodrugs,
pubmed-meshheading:18981010-Vomiting
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
A phase 1 open-label, accelerated dose-escalation study of the hypoxia-activated prodrug AQ4N in patients with advanced malignancies.
|
|
pubmed:affiliation |
Institute for Drug Development, Cancer Therapy and Research Center, University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA. kyri.papadopoulos@start.stoh.com
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase I
|
